- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00477594
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia
An Open-Label Extension Study to Assess the Long-term Safety and Efficacy of Mipomersen in Subjects With Familial Hypercholesterolemia
Study Overview
Status
Conditions
- Metabolic Diseases
- Congenital Abnormalities
- Infant, Newborn, Diseases
- Genetic Diseases, Inborn
- Dyslipidemias
- Metabolism, Inborn Errors
- Lipid Metabolism Disorders
- Hypercholesterolemia
- Hyperlipidemias
- Hyperlipoproteinemias
- Lipid Metabolism, Inborn Errors
- Hyperlipoproteinemia Type II
- Metabolic Disorder
- Hypercholesterolemia, Autosomal Dominant
Intervention / Treatment
Detailed Description
Familial Hypercholesterolemia (FH) is an autosomal dominant metabolic disorder characterized by markedly elevated low density lipoprotein (LDL), premature onset of atherosclerosis, and development of xanthomata. There are two distinct subpopulations that have a high unmet medical need due to the lack of alternative therapy: homozygotes, who have two defective LDL receptor (LDL-R) genes, and heterozygotes with a history of cardiovascular disease (CVD) on maximally tolerated therapy. Treatment for FH is directed at lowering plasma levels of LDL-C.
Mipomersen is an antisense drug targeted to human apolipoprotein B (apoB), the principal apolipoprotein of atherogenic LDL-C and its metabolic precursor, very low density lipoprotein (VLDL). Mipomersen is complimentary to the coding region of the messenger ribonucleic acid (mRNA) for apo-B. Inhibition of apo-B would be expected to impair VLDL synthesis and result in lowered levels of LDL-C.
In early clinical trials, mipomersen has been shown to reduce levels of LDL-C to recommended target levels in some participants.
This was an open-label extension study, which consisted of a ≤2-week screening period, up to 3 years of treatment with mipomersen, and a 24-week post-treatment follow-up period. Patients who participated in Cohorts A, B, or C in study 301012-CS9 were randomized in a 1:1 ratio to mipomersen 200 mg once a week (QW) or 200 mg mipomersen every other week (QOW) for up to 3 years. Patients randomized to mipomersen 200 mg QOW were allowed to receive mipomersen 200 mg QW at the Investigator's discretion after the first 52 weeks of the treatment period. Patients who participated in study 301012-CS8 or Cohort D of study 301012-CS9 received 200 mg mipomersen QW for up to 3 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60654
-
-
Maine
-
Auburn, Maine, United States, 04210
-
Biddeford, Maine, United States, 04005
-
Scarborough, Maine, United States, 04074
-
-
Ohio
-
Cincinnati, Ohio, United States, 45212
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Satisfactory completion of dosing and Week 7 or Week 15 assessments (depending on the treatment and dose received) in their initial study (Protocol 301012-CS8 (NCT00280995) or 301012-CS9 (NCT00281008)).
Exclusion Criteria:
- Have a new condition or worsening of existing condition which in the opinion of the Investigator would make the patient unsuitable for enrollment, or could interfere with patient's participation in or completion of the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mipomersen 200 mg per week
Participants received 200 mg mipomersen once a week by subcutaneous injection, for up to 3 years.
|
200 mg/ml, in 1 ml solution for subcutaneous injection.
Other Names:
|
Experimental: Mipomersen 200 mg every other week
Participants received 200 mg mipomersen every other week by subcutaneous injection, for up to 3 years.
Participants could receive mipomersen 200 mg once a week at the Investigator's discretion after the first 52 weeks of the treatment period.
|
200 mg/ml, in 1 ml solution for subcutaneous injection.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C)
Time Frame: Baseline and Weeks 52 and 104
|
LDL cholesterol was measured in mg/dL.
Samples were taken following an overnight fast.
For patients with triglycerides <400 mg/dL, LDL-C was obtained using Friedewald's calculation; and for patients with triglycerides ≥400 mg/dL, LDL-C was directly measured by the central laboratory using ultracentrifugation.
For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study.
For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.
|
Baseline and Weeks 52 and 104
|
Low-density Lipoprotein Cholesterol (LDL-C) Over Time
Time Frame: Baseline and Weeks 52 and 104.
|
Samples were taken following an overnight fast.
For patients with triglycerides <400 mg/dL, LDL-C was obtained using Friedewald's calculation; and for patients with triglycerides ≥400 mg/dL, LDL-C was directly measured by the central laboratory using ultracentrifugation.
For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study.
For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.
|
Baseline and Weeks 52 and 104.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline in Apolipoprotein B
Time Frame: Baseline and Weeks 52 and 104
|
Apolipoprotein B was measured in mg/dL.
Samples were taken following an overnight fast.
For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study.
For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.
|
Baseline and Weeks 52 and 104
|
Apolipoprotein B Over Time
Time Frame: Baseline and Weeks 52 and 104.
|
For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study.
For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.
|
Baseline and Weeks 52 and 104.
|
Percent Change From Baseline in Total Cholesterol
Time Frame: Baseline and Weeks 52 and 104.
|
Total cholesterol was measured in mg/dL.
Samples were taken following an overnight fast.
|
Baseline and Weeks 52 and 104.
|
Total Cholesterol Over Time
Time Frame: Baseline and Weeks 52 and 104.
|
For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study.
For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.
|
Baseline and Weeks 52 and 104.
|
Percent Change From Baseline in Non-High-Density Lipoprotein Cholesterol
Time Frame: Baseline and Weeks 52 and 104.
|
Non-high-density lipoprotein cholesterol was measured in mg/dL.
Samples were taken following an overnight fast.
|
Baseline and Weeks 52 and 104.
|
Non-High-Density Lipoprotein Cholesterol Over Time
Time Frame: Baseline and Weeks 52 and 104.
|
For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study.
For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.
|
Baseline and Weeks 52 and 104.
|
Number of Participants With Treatment-Emergent Adverse Events (AEs)
Time Frame: 2 years
|
AEs were considered as related if assessed by the Investigator as possibly, probably or definitely related to study drug.
The severity of each event was assessed using the following categories: Mild (symptom(s) barely noticeable to the patient or do not make the patient uncomfortable); Moderate (symptom(s) of a sufficient severity to make the patient uncomfortable, performance of daily activities is influenced) or Severe (symptom(s) of a sufficient severity to cause the patient severe discomfort, may cause cessation of treatment with the study drug).
Serious AEs (SAEs) are those that resulted in death, were life-threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability/incapacity, congenital anomaly, or resulted in an important medical event that may have jeopardized the patient or required medical or surgical intervention to prevent one of the outcomes listed above.
|
2 years
|
Percent Change From Baseline in Clinical Chemistry Parameters
Time Frame: Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.
|
Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.
|
|
Percent Change From Baseline in Hematology Parameters
Time Frame: Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment
|
Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment
|
|
Percent Change From Baseline in Blood Pressure
Time Frame: Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.
|
Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.
|
|
Percent Change From Baseline in Pulse Rate
Time Frame: Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.
|
Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.
|
|
Percent Change From Baseline in Respiratory Rate
Time Frame: Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.
|
Baseline and Week 104 or the Early Termination visit for participants who did not complete 2 years of treatment.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Change From Baseline in Triglycerides
Time Frame: Baseline and Weeks 52 and 104.
|
Triglycerides were measured in mg/dL.
Samples were taken following an overnight fast.
|
Baseline and Weeks 52 and 104.
|
Triglycerides Over Time
Time Frame: Baseline and Weeks 52 and 104.
|
For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study.
For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.
|
Baseline and Weeks 52 and 104.
|
Percent Change From Baseline in Lipoprotein(a)
Time Frame: Baseline and Weeks 52 and 104.
|
Lipoprotein(a) was measured in mg/dL.
Samples were taken following an overnight fast.
|
Baseline and Weeks 52 and 104.
|
Lipoprotein(a) Over Time
Time Frame: Baseline and Weeks 52 and 104.
|
For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study.
For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.
|
Baseline and Weeks 52 and 104.
|
Percent Change From Baseline in Very-Low-Density Lipoprotein (VLDL) Cholesterol
Time Frame: Baseline and Weeks 52 and 104.
|
Very-Low-Density Lipoprotein (VLDL) Cholesterol was measured in mg/dL.
Samples were taken following an overnight fast.
|
Baseline and Weeks 52 and 104.
|
Very-Low-Density Lipoprotein (VLDL) Cholesterol Over Time
Time Frame: Baseline and Weeks 52 and 104.
|
For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study.
For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.
|
Baseline and Weeks 52 and 104.
|
Percent Change From Baseline in Ratio of Low-density Lipoprotein Cholesterol to High-density Lipoprotein Cholesterol
Time Frame: Baseline and Weeks 52 and 104.
|
Baseline and Weeks 52 and 104.
|
|
Ratio of Low-density Lipoprotein Cholesterol to High-density Lipoprotein Cholesterol Over Time
Time Frame: Baseline and Weeks 52 and 104.
|
For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study.
For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.
|
Baseline and Weeks 52 and 104.
|
Percent Change From Baseline in Apolipoprotein A1
Time Frame: Baseline and Weeks 52 and 104.
|
Apolipoprotein A1 was measured in mg/dL.
Samples were taken following an overnight fast.
|
Baseline and Weeks 52 and 104.
|
Apolipoprotein A1 Over Time
Time Frame: Baseline and Weeks 52 and 104.
|
For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study.
For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.
|
Baseline and Weeks 52 and 104.
|
Percent Change From Baseline in High-Density Lipoprotein Cholesterol
Time Frame: Baseline and Weeks 52 and 104.
|
High-Density Lipoprotein (HDL) Cholesterol was measured in mg/dL.
Samples were taken following an overnight fast.
|
Baseline and Weeks 52 and 104.
|
High-Density Lipoprotein Cholesterol Over Time
Time Frame: Baseline and Weeks 52 and 104.
|
For patients who were on placebo in the index study or who took their last dose of mipomersen ≥6 months prior to first dose in this study, Baseline is defined as the last measurement prior to first dose in this study.
For participants who took their last dose of mipomersen less than 6 months before starting this study, Baseline is defined as the last measurement taken prior to receiving a first dose in the index study.
|
Baseline and Weeks 52 and 104.
|
Collaborators and Investigators
Sponsor
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Disease
- Dyslipidemias
- Congenital Abnormalities
- Hypercholesterolemia
- Hyperlipidemias
- Metabolism, Inborn Errors
- Metabolic Diseases
- Hyperlipoproteinemia Type II
- Lipid Metabolism Disorders
- Genetic Diseases, Inborn
- Infant, Newborn, Diseases
- Hyperlipoproteinemias
- Lipid Metabolism, Inborn Errors
- Molecular Mechanisms of Pharmacological Action
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Mipomersen
Other Study ID Numbers
- 301012-CS17
- 2007-001024-12 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metabolic Diseases
-
Mondelēz International, Inc.University of SydneyCompletedMetabolic DisorderAustralia
-
Asia UniversityDepartment of Health, Executive Yuan, R.O.C. (Taiwan)Completed
-
San Diego State UniversityNot yet recruitingBone Disease, Metabolic
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Stichting MetakidsCompletedInherited Metabolic DisordersNetherlands
-
Hospital Clinic of BarcelonaNovartisCompletedBone Disease, MetabolicSpain
-
Nantes University HospitalCentre de Recherche en Nutrition Humaine Ouest (CRNH)CompletedCholesterol; Metabolic Disorder | LipoproteinemiaFrance
-
Istituto Ortopedico RizzoliCompletedOsteopenia | Bone Disease, MetabolicItaly
-
University of AarhusAxellusUnknownMetabolic Bone DisorderDenmark
-
Istituto Ortopedico GaleazziUnknownPhysical Activity | Bone Disease, MetabolicItaly
Clinical Trials on mipomersen sodium
-
Kastle Therapeutics, LLCCompletedHypercholesterolemia | Heterozygous FamilialUnited States, Italy, Poland, Ukraine, United Kingdom, Germany, Hong Kong, Taiwan, Spain, Argentina, Belgium, Israel, Malaysia, South Africa, Turkey, Netherlands, Korea, Republic of, Canada, New Zealand, Russian Federation, Brazil, Austral... and more
-
Kastle Therapeutics, LLCIonis Pharmaceuticals, Inc.CompletedMetabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Lipid Metabolism, Inborn Errors | Hypobetalipoproteinemias | Hypolipoproteinemias | Hypolipopro... and other conditionsNetherlands
-
Kastle Therapeutics, LLCIonis Pharmaceuticals, Inc.CompletedMetabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Hyperlipoproteinemias | Lipid Metabolism, Inborn Errors | Hyperlipoproteinemia Type II | Metabolic... and other conditionsUnited States, Taiwan, Brazil, Canada, South Africa, United Kingdom, Singapore
-
Kastle Therapeutics, LLCIonis Pharmaceuticals, Inc.Completed
-
Kastle Therapeutics, LLCIonis Pharmaceuticals, Inc.CompletedMetabolic Diseases | Dyslipidemias | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Metabolic DisorderNetherlands
-
Kastle Therapeutics, LLCIonis Pharmaceuticals, Inc.CompletedHypercholesterolemia | Coronary Heart DiseaseSouth Africa, Germany, United States, United Kingdom, Canada, Czech Republic
-
Kastle Therapeutics, LLCIonis Pharmaceuticals, Inc.CompletedCoronary Artery Disease | Heterozygous Familial HypercholesterolemiaUnited States, Canada
-
Kastle Therapeutics, LLCIonis Pharmaceuticals, Inc.CompletedMetabolic Diseases | Congenital Abnormalities | Infant, Newborn, Diseases | Genetic Diseases, Inborn | Dyslipidemias | Metabolism, Inborn Errors | Lipid Metabolism Disorders | Hypercholesterolemia | Hyperlipidemias | Hyperlipoproteinemias | Lipid Metabolism, Inborn Errors | Hyperlipoproteinemia Type II | Metabolic... and other conditionsUnited States, Canada, Brazil, Taiwan, Singapore, South Africa, United Kingdom
-
Kastle Therapeutics, LLCIonis Pharmaceuticals, Inc.CompletedHypercholesterolemia | Coronary Heart DiseaseUnited States
-
Kastle Therapeutics, LLCIonis Pharmaceuticals, Inc.CompletedHealthy VolunteerUnited States